Skip to main content
SMS Pharmaceuticals Ltd logo

SMS Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · SMSPHARMA ISIN · INE812G01025 LEI · 335800XXEADQCB7GJ514 BSE.NS Manufacturing
Open in API
Filings indexed 747 across all filing types
Latest filing 2024-05-29 Regulatory Filings
Country IN India
Listing BSE.NS SMSPHARMA

About SMS Pharmaceuticals Ltd

https://smspharma.com/

SMS Pharmaceuticals Ltd specializes in the development and large-scale manufacturing of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. The organization operates multiple manufacturing units and research centers, maintaining compliance with international regulatory standards including USFDA approvals. Its core product portfolio covers therapeutic areas such as anti-ulcerants, anti-migraine agents, anti-hypertensives, and anti-retrovirals. Beyond its proprietary product line, the company provides Contract Research and Manufacturing Services (CRAMS), offering expertise in process development, chemical synthesis, and analytical validation. The company focuses on delivering high-quality chemical solutions through integrated research and development capabilities, supporting global supply chains with a commitment to technical excellence and operational efficiency.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Regulatory Filings
2024-05-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is an invitation notice for an investor conference call scheduled to discuss the company's financial performance for the quarter and year ended 31st March 2024. It is addressed to stock exchanges and includes call details and participant names. There is no actual financial data or report content included, only an announcement of the upcoming call. According to the definitions, a full transcript of the call would be classified as a Call Transcript (CT), but this document is only the invitation to the call, not the transcript itself. Therefore, the best fitting category is Call Transcript (CT) as it relates directly to the conference call event, but since it is only an invitation, it is still most appropriate to classify it as a Call Transcript (CT) because no other category fits better and it is not a report publication announcement or regulatory filing. Confidence is high due to clear identification of the document as a conference call invitation.
2024-05-27 English
Board Meeting — SMS PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 29-May-2024 to consider and approve the Yearly Audited Financial results of the Company for the…
Regulatory Filings
2024-05-22 English
Board Meeting — Financial Results/Dividend/Other business matters
Board/Management Information Classification · 95% confidence The document is a notice from SMS Pharmaceuticals Limited addressed to stock exchanges about an upcoming Board Meeting scheduled for 29th May 2024. The agenda includes consideration and approval of the audited financial statements for the fiscal year ended 31st March 2024 and recommendation of dividend. It also mentions the closure of the trading window as per insider trading regulations. The document is short (1871 characters) and serves as an intimation or announcement of a future board meeting and related agenda items, not the actual financial statements or reports themselves. Therefore, it is best classified as a Board/Management Information filing, which covers announcements of board meetings and related corporate governance matters.
2024-05-22 English
Monitoring Agency Report
Capital/Financing Update Classification · 95% confidence The document is a Monitoring Agency Report related to the utilization of proceeds from a preferential issue of convertible warrants by SMS Pharmaceuticals Limited for the quarter ended March 31, 2024. It references SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and includes detailed information on the issue size, utilization of funds, and compliance with the offer document. The report is prepared by CARE Ratings Limited as the Monitoring Agency. This type of report is a regulatory compliance document specifically monitoring the use of capital raised through a private placement, which aligns with the category of Capital/Financing Update (CAP). It is not an annual or interim financial report, nor is it a simple announcement or certification. The document length and content confirm it is the report itself, not just an announcement. Therefore, the appropriate classification is CAP.
2024-05-14 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2024-05-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.